【杰富瑞下调石药集团评级，调整营收及利润预测】6月3日，杰富瑞发布研究报告指出，石药集团股价年初至今累计涨幅达70%，仅过去两周就涨超三成。这主要源于市场对其商业开发潜力的高预期及盈利拐点的憧憬，但如今利好因素似已反映在股价上。 尽管管理层透露今年或达成三项规模达50亿美元的授权交易，但杰富瑞认为达成交易并非易事。此外，恩必普等核心产品销售持续面临下行风险，预计恩必普注射液及胶囊销售额将从去年的...
Source Link【杰富瑞下调石药集团评级，调整营收及利润预测】6月3日，杰富瑞发布研究报告指出，石药集团股价年初至今累计涨幅达70%，仅过去两周就涨超三成。这主要源于市场对其商业开发潜力的高预期及盈利拐点的憧憬，但如今利好因素似已反映在股价上。 尽管管理层透露今年或达成三项规模达50亿美元的授权交易，但杰富瑞认为达成交易并非易事。此外，恩必普等核心产品销售持续面临下行风险，预计恩必普注射液及胶囊销售额将从去年的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.